Ergoteles’s Forte Biosciences FBRX Stock Holding History

Ergoteles’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-728	Closed	-$19K	–	1586
2022 Q3	$19K	Sell	728 -1,288	-64%	-$40.9K	﹤0.01%	1472
2022 Q2	$66K	Buy	+2,016	New	+$64K	﹤0.01%	1549

Other funds holding FBRX

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

OWP

Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ergoteles's FBRX Position: Q4 2022 in Review

Ergoteles sold out of Forte Biosciences (FBRX) in Q4 2022, closing a stake of 728 shares — an estimated $19K sold.

Ergoteles first reported a position in FBRX in Q2 2022 and held it in 2 quarters. The position peaked at $66K in Q2 2022. 34 funds tracked by Wall St. Rank hold FBRX as of Q4 2022.

Ergoteles reported no remaining Forte Biosciences position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 728 Forte Biosciences shares in Q4 2022, an estimated $19K.
Ergoteles first reported a position in Forte Biosciences in Q2 2022 and held it in 2 quarters.
Ergoteles's Forte Biosciences position peaked at $66K in Q2 2022.
34 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.